XTX Topco Ltd Grows Stake in argenex SE (NASDAQ:ARGX)

Key Points

• XTX Topco Ltd significantly increased its stake in argenex SE by 171.7%, owning 5,543 shares valued at $3,281,000 after acquiring an additional 3,503 shares in Q1.
• Multiple institutional investors have also boosted their holdings in argenex, including FMR LLC with a position worth $3.45 billion and GAMMA Investing LLC who increased holdings by 53,684.9% to $802.2 million.
• Analysts generally have a positive outlook on argenex, with an average rating of "Buy" and a price target averaging $728.06 across various analysts.

XTX Topco Ltd grew its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 171.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,543 shares of the company's stock after buying an additional 3,503 shares during the quarter. XTX Topco Ltd's holdings in argenex were worth $3,281,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of the company. FMR LLC increased its holdings in shares of argenex by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of argenex during the fourth quarter worth about $91,013,000. GAMMA Investing LLC grew its stake in argenex by 53,684.9% in the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after purchasing an additional 135,286 shares in the last quarter. Marshall Wace LLP lifted its position in shares of argenex by 184.7% in the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after buying an additional 124,271 shares during the last quarter. Finally, Capital World Investors grew its position in shares of argenex by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after purchasing an additional 86,687 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on ARGX shares. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and issued a $715.00 price objective on shares of argenex in a research note on Monday, July 21st. Citigroup restated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Guggenheim boosted their target price on shares of argenex from $1,060.00 to $1,070.00 and gave the company a "buy" rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, July 8th. Nineteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $736.81.

argenex Trading Up 0.5%

Shares of NASDAQ ARGX traded up $3.47 during mid-day trading on Friday, reaching $673.80. The company had a trading volume of 633,642 shares, compared to its average volume of 414,608. The business's 50-day moving average is $571.11 and its 200-day moving average is $597.21. The stock has a market cap of $41.24 billion, a price-to-earnings ratio of 34.55, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39. argenex SE has a 52 week low of $475.65 and a 52 week high of $689.13.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 33.30% and a net margin of 40.98%. As a group, equities research analysts forecast that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.